Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study

Patients with peripheral arterial disease (PAD) benefit from combination therapy with acetylsalicylic acid (ASA, 100 mg, one time per day) plus low-dose rivaroxaban (2.5 mg, two times per day) compared to ASA monotherapy. In particular, major adverse cardiac and limb events were significantly reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurk, Kerstin, Rothenaicher, Korbinian F., Groß, Kathrin, Rossmann, Heidi, Weißer, Gerhard, Schmidtmann, Irene, Münzel, Thomas, Espinola-Klein, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120432/
https://www.ncbi.nlm.nih.gov/pubmed/35600474
http://dx.doi.org/10.3389/fcvm.2022.865166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120432/
https://www.ncbi.nlm.nih.gov/pubmed/35600474
http://dx.doi.org/10.3389/fcvm.2022.865166

Ejemplares similares